Travere Therapeutics (TVTX) Tops Q4 EPS by 41c
Tweet
Share
E-mailGet Alerts TVTX Hot Sheet
Join SI Premium – FREE
Travere Therapeutics (NASDAQ: TVTX) reported Q4 EPS of $0.37, $0.41 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $129.69 million versus the consensus estimate of $145.23 million.
For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
- JPMorgan Upgrades IBM (IBM) to Overweight
- Keurig Dr Pepper coffee chief to depart ahead of planned split
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
